| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Ryan Langston maintains Astrana Health (NASDAQ:ASTH) with a Buy and lowers the price target from $40 to $35.
BTIG analyst David Larsen maintains Astrana Health (NASDAQ:ASTH) with a Buy and lowers the price target from $50 to $45.
2025 Guidance:Astrana is providing the following updated guidance for total revenue and Adjusted EBITDA for the year ending Dec...
Astrana Health (NASDAQ:ASTH) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.4...
Astrana Health (NASDAQ:ASTH) affirms FY2025 sales outlook from $3.100 billion-$3.300 billion to $3.100 billion-$3.300 billion v...